Your browser doesn't support javascript.
loading
Patients presenting with metastases: stage IV uveal melanoma, an international study.
Garg, Gaurav; Finger, Paul T; Kivelä, Tero T; Simpson, E Rand; Gallie, Brenda L; Saakyan, Svetlana; Amiryan, Anush G; Valskiy, Vladimir; Chin, Kimberly J; Semenova, Ekaterina; Seregard, Stefan; Filì, Maria; Wilson, Matthew; Haik, Barrett; Caminal, Josep Maria; Catala-Mora, Jaume; Gutiérrez, Cristina; Pelayes, David E; Folgar, Anibal Martin; Jager, Martine Johanna; Dogrusöz, Mehmet; Luyten, Gregorius P M; Singh, Arun D; Suzuki, Shigenobu.
Afiliação
  • Garg G; Department of Ocular Tumor, Orbital Disease, Ophthalmic Radiation Therapy, New York Eye Cancer Center, New York, New York, USA.
  • Finger PT; Department of Ocular Tumor, Orbital Disease, Ophthalmic Radiation Therapy, New York Eye Cancer Center, New York, New York, USA pfinger@eyecancer.com.
  • Kivelä TT; Ocular Oncology Service, Helsinki University Central Hospital, Helsinki, Finland.
  • Simpson ER; Department of Ocular Oncology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
  • Gallie BL; Departments of Molecular Medical Genetics, Medical Biophysics, and Ophthalmology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada.
  • Saakyan S; Department of Ophthalmic Oncology and Radiology, Moscow Helmholtz Research Institute of Eye Diseases, Moskva, Russian Federation.
  • Amiryan AG; Department of Ophthalmic Oncology and Radiology, Moscow Helmholtz Research Institute of Eye Diseases, Moskva, Russian Federation.
  • Valskiy V; Department of Ophthalmic Oncology and Radiology, Moscow Helmholtz Research Institute of Eye Diseases, Moskva, Russian Federation.
  • Chin KJ; Department of Ocular Tumor, Orbital Disease, Ophthalmic Radiation Therapy, New York Eye Cancer Center, New York, New York, USA.
  • Semenova E; Department of Ocular Tumor, Orbital Disease, Ophthalmic Radiation Therapy, New York Eye Cancer Center, New York, New York, USA.
  • Seregard S; Department of Ophthalmic Pathology and Oncology, Saint Eriks Eye Hospital, Stockholm, Sweden.
  • Filì M; Department of Ophthalmic Pathology and Oncology, Saint Eriks Eye Hospital, Stockholm, Sweden.
  • Wilson M; The Ophthalmic Oncology Service, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Haik B; The Ophthalmic Oncology Service, Hamilton Eye Institute, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Caminal JM; Ocular Oncology Service, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Catala-Mora J; Ocular Oncology Service, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Gutiérrez C; Ocular Oncology Service, Bellvitge University Hospital, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Pelayes DE; Department of Ophthalmic Oncology, Hospital General de Agudos Carlos G Durand, Buenos Aires, Argentina.
  • Folgar AM; Department of Ophthalmic Oncology, Hospital General de Agudos Carlos G Durand, Buenos Aires, Argentina.
  • Jager MJ; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
  • Dogrusöz M; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
  • Luyten GPM; Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands.
  • Singh AD; Department of Ophthalmic Oncology, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
  • Suzuki S; Department of Ophthalmic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Br J Ophthalmol ; 106(4): 510-517, 2022 04.
Article em En | MEDLINE | ID: mdl-33452185
OBJECTIVE: To analyse ocular and systemic findings of patients presenting with systemic metastasis. METHODS AND ANALYSIS: It is an international, multicentre, internet-enabled, registry-based retrospective data analysis. Patients were diagnosed between 2001 and 2011. Data included: primary tumour dimensions, extrascleral extension, ciliary body involvement, American Joint Committee on Cancer (AJCC)-tumour, node, metastasis staging, characteristics of metastases. RESULTS: Of 3610 patients with uveal melanoma, 69 (1.9%; 95% CI 1.5 to 2.4) presented with clinical metastasis (stage IV). These melanomas originated in the iris, ciliary body and choroid in 4%, 16% and 80% of eyes, respectively. Using eighth edition AJCC, 8 (11%), 20 (29%), 24 (35%), and 17 (25%) belonged to AJCC T-categories T1-T4. Risk of synchronous metastases increased from 0.7% (T1) to 1.5% (T2), 2.6% (T3) and 7.9% (T4). Regional lymph node metastases (N1a) were detected in 9 (13%) patients of whom 6 (67%) had extrascleral extension. Stage of systemic metastases (known for 40 (59%) stage IV patients) revealed 14 (35%), 25 (63%) and 1 (2%) had small (M1a), medium-sized (M1b) and large-sized (M1c) metastases, respectively. Location of metastases in stage IV patients were liver (91%), lung (16%), bone (9%), brain (6%), subcutaneous tissue (4%) and others (5%). Multiple sites of metastases were noted in 24%. Compared with the 98.1% of patients who did not present with metastases, those with synchronous metastases had larger intraocular tumours, more frequent extrascleral extension, ciliary body involvement and thus a higher AJCC T-category. CONCLUSIONS: Though higher AJCC T-stage was associated with risk for metastases at diagnosis, even small T1 tumours were stage IV at initial presentation. The liver was the most common site of metastases; however, frequent multiorgan involvement supports initial whole-body staging.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Uveais / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Uveais / Melanoma Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article